Efavirenz plasma concentrations and efficiency

AIDS

Volumn 15, Issue 9, 2001, Pages 1192-1193

  Lopez Cortes L F ^a   De Alarcon A ^a   Viciana, P ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ;

BODY MASS; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEDICAL RESEARCH; METHODOLOGY; PATIENT COMPLIANCE; PEER REVIEW; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 0035876396     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00022     Document Type: Letter

References (2)

1. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
2. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy